{"id":"NCT00330681","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)","officialTitle":"A Confirmatory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-blind, Parallel-group, Placebo-controlled Manner.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2008-09","completion":"2008-09","firstPosted":"2006-05-29","resultsPosted":"2017-05-17","lastUpdate":"2017-05-17"},"enrollment":206,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"interventions":[{"type":"DRUG","name":"MCI-186","otherNames":["Edaravone","Radicut"]},{"type":"DRUG","name":"Placebo of MCI-186","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip once a day in patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. And in addition, this study will be performed to examine the safety of MCI-186 to ALS patients.","primaryOutcome":{"measure":"Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks","timeFrame":"baseline and 24 weeks","effectByArm":[{"arm":"MCI-186","deltaMin":-5.7,"sd":0.85},{"arm":"Placebo of MCI-186","deltaMin":-6.35,"sd":0.84}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25286015"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":102},"commonTop":["Nasopharyngitis","Gait disturbance","Constipation","Insomnia","Contusion"]}}